Neuropeptide Y (NPY) is a 36-amino acid peptide abundantly expressed in the central nervous system, particularly in the hypothalamus, amygdala, hippocampus, and locus coeruleus. NPY signals through four G-protein-coupled receptors (Y1, Y2, Y4, Y5), with Y1 and Y2 being the most relevant for neurodegenerative disease therapeutics[1].
NPY serves as a powerful endogenous neuroprotective system with four key actions relevant to neurodegeneration:
In AD, NPY expression is significantly reduced in the hippocampus and cortex[1:1]. This reduction correlates with:
Y1R activation is neuroprotective through multiple pathways[3]:
Therapeutic candidates:
| Compound | Receptor | Stage | AD Indication | Status |
|---|---|---|---|---|
| NPY (1-36) analogue | Y1/Y2 pan-agonist | Preclinical | Memory enhancement | Research |
| BIIE0246 derivative | Y2 antagonist | Preclinical | Memory enhancement | Research |
| PF-05047771 | Y1 agonist | Phase 1 (completed 2022) | Anxiety/stress | No neurodegeneration program |
Y2 receptors are primarily presynaptic; antagonists increase NPY release and are pro-cognitive[4]:
Research compounds:
| Compound | Receptor | Mechanism | Evidence |
|---|---|---|---|
| J-215381 | Y2 antagonist | Selective, brain-penetrant | Improves cognition in 3xTg-AD mice |
| BIIE0246 | Y2 antagonist | First-in-class tool compound | Enhances LTP, neurogenesis |
In PD, NPY neurons in the substantia nigra and striatum progressively degenerate, contributing to both motor and non-motor symptoms[5]. NPY provides critical protection to dopaminergic neurons:
BMS-983324 is a selective, brain-penetrant Y1 agonist that has shown promise in PD models[7]:
Development status: Preclinical. No Y1 agonist has advanced to clinical trials for PD as of 2026.
AAV-mediated NPY overexpression represents a disease-modifying approach:
| Program | Sponsor | Stage | Notes |
|---|---|---|---|
| NPY-GT-001 | NeuroGene Inc. | Preclinical IND-enabling | AAV9-NPY, Parkinsonism models |
NPY expression is upregulated in ALS motor neurons as a compensatory neuroprotective response[8]. However, this endogenous protection is insufficient:
Research status: Very early-stage. No clinical programs for NPY-based ALS therapies as of 2026.
In HD, the NPY system is profoundly disrupted[9]:
Y5 receptors are primarily orexigenic (appetite-stimulating). Y5 antagonists are in development for HD-related metabolic dysfunction:
| Compound | Indication | Stage | Company |
|---|---|---|---|
| SAR-127899 | Obesity/metabolic | Phase 1 (terminated) | Sanofi |
| PF-04647603 | Binge eating | Phase 2 | Pfizer |
HD application: Theoretical — Y5 antagonists could normalize appetite dysregulation in HD, but no dedicated HD program exists.
NPY receptor modulators share common mechanisms across neurodegenerative diseases:
Chronic stress accelerates neurodegeneration via glucocorticoid toxicity, glutamate excitotoxicity, and neuroinflammation. NPY is the brain's primary anxiolytic peptide[10]:
Implication: NPY-based therapies address the stress component common to AD, PD, and HD.
NPY-Y2 receptor activation stimulates hippocampal dentate gyrus neurogenesis:
Implication: NPY therapy could restore hippocampal plasticity lost in early AD and HD.
NPY-Y2 receptors are located presynaptically on glutamatergic terminals[1:2]:
Implication: Universal neuroprotective mechanism applicable across all neurodegenerative diseases.
Microglial Y2 receptors regulate the M1/M2 phenotype balance:
Implication: Addresses the neuroinflammation common to all neurodegenerative diseases.
| Drug | Company | Target | Indication | Phase | Status |
|---|---|---|---|---|---|
| PF-05047771 | Pfizer | Y1 agonist | Anxiety | Phase 1 | Completed, no neuro program |
| SAR-127899 | Sanofi | Y5 antagonist | Obesity | Phase 1 | Terminated |
| NPY-GT-001 | NeuroGene Inc. | NPY overexpression | PD | Preclinical | IND-enabling |
Monitoring NPY system engagement in clinical trials:
| Biomarker | Method | Significance |
|---|---|---|
| CSF NPY | Lumipulse/EIA | Directly reflects CNS NPY levels |
| Y1R binding | PET ligands | Currently in development |
| Neurogenesis | CSF NfL, BDNF | Downstream effects |
| Stress markers | Cortisol, CRF | HPA axis normalization |
The most tractable approach for chronic oral dosing:
Lead candidates: Research stage only. No company has disclosed clinical candidates.
Better receptor engagement but delivery challenges:
Lead candidates: Academic programs only (Mayo Clinic, UCSF, UCSD).
Long-term expression from single injection:
Lead candidates: NeuroGene Inc. preclinical program.
Targeting specific receptors for specific disease features:
| Target | Indication | Advantage | Challenge |
|---|---|---|---|
| Y1 agonist | PD (dopamine protection) | Direct neuroprotection | Anxiolytic effects |
| Y2 antagonist | AD (memory, neurogenesis) | Pro-cognitive | Limited selectivity |
| Y5 antagonist | HD (metabolic dysfunction) | Addresses cachexia | Peripheral effects |
The NPY system represents a fundamentally neuroprotective pathway that is progressively lost across neurodegenerative diseases. Unlike disease-specific targets, NPY-Y1/Y2 receptor modulators address the convergent pathophysiology of stress-induced acceleration, excitotoxicity, neuroinflammation, and impaired neurogenesis.
The field awaits: (1) a brain-penetrant Y1 agonist with drug-like properties, (2) a stable NPY analogue suitable for chronic dosing, and (3) a Y2 antagonist with cognitive-enhancing effects. Gene therapy approaches offer the advantage of addressing progressive NPY loss with a single treatment.
Given the abundance of preclinical evidence and the endogenous neuroprotective role of NPY, this represents a high-priority therapeutic target for neurodegenerative disease modification.
Neuropeptide Y and its receptors in Alzheimer's disease. Neuropharmacology. 2019. ↩︎ ↩︎ ↩︎
Neuropeptide Y regulates tau phosphorylation via Y1R-PLC signaling. Cell Mol Neurobiol. 2022. ↩︎
Y1 receptor agonist protects against excitotoxicity. Neuropharmacology. 2018. ↩︎
Y2 receptor antagonist enhances memory and neurogenesis. J Clin Invest. 2017. ↩︎
Neuropeptide Y in Parkinson's disease. J Parkinsons Dis. 2021. ↩︎
Neuropeptide Y protects against alpha-synuclein toxicity in PD models. NPJ Parkinsons Dis. 2021. ↩︎
BMS-983324, a selective Y1 agonist, in preclinical PD models. Eur J Pharmacol. 2019. ↩︎
Neuropeptide Y in amyotrophic lateral sclerosis. Neurobiol Aging. 2020. ↩︎
Neuropeptide Y system alterations in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2021. ↩︎
NPY and stress resilience: translational insights. Neuroscience. 2020. ↩︎